“In 2019, TheragenEtex Bio Institute established a company specializing in anti-cancer treatment vaccines called, ‘TheraCanVac’ in order to conduct research on the next generation of anti-cancer immunotherapy and to develop customized cancer vaccines for all individuals through the use of Neo-Antigen.”
Immunotherapy using cancer antigens can guarantee clinical safety and be applied on terminally-ill patients or relapsing patients, thus gaining a lot of attention from the field of precision medicine due to its innovative features.
TheragenEtex has been developing advanced technologies for the field of NGS and bioinformation for the past 10 years, and based on this development, it offers world-class accuracy in forecasting cancer antigens.
TheragenEtex is devoting itself to research and development to provide the opportunity of new treatment for cancer patients with the newest genome-based technology.”
Scope of Research & Development
Responses of T-cells are important in immunotherapy. Immunotherapy uses the principle of making the T-cells attack cancer cells by switching a “cold tumor,” in a state of exhaustion and immune response, into a “hot tumor.”
Anticancer therapy, which regulates immune responses, provides great effects to relapsing cancer patients and metastatic cancer patients who show tolerance against existing radiation and chemotherapy, providing a new treatment opportunity for patients who do not benefit from existing treatments. In particular, it can be applied as a new treatment method for patients who cannot use molecularly targeted therapy such as immune checkpoint inhibitors.
Cancer vaccines are a type of immunotherapy that remove cancer cells with improved immune function in the bodies of cancer patients by activating the immune system with cancer-specific antigens.
In particular, it can improve patients’ response rates to drug and survival rates with the methods of Viral Vector Vaccine and dendritic cell-based vaccine, such as peptide, RNA, and DNA vaccines, and tumor antigens, to increase immunity.”
<DCs-based immunotherapeutic strategies (J Carcinog Mutagen 2015, Vol 6(2): 222)>
A. Shared Antigen
By administering shared antigens, which are particularly elevated in cancer patients, it activates the immune system and helps attack cancer cells. However, patients who do not have shared antigens will experience a limitation in treatment effects. Adjuvant or a combination with antibody-based immunotherapy can be used to overcome such limitations.
B. Private Neo-Antigen
Cancer can be treated by administering vaccines to patients through an NGS analysis of antigens which are predicted differently depending on the cancer patient–unlike shared neo-antigens–and by producing vaccines that use antigens. This vaccine is specific for Korean characteristics and an accurate antigen prediction model should be established for treatment.
C. Dentritic cell Based Cancer Vaccine
One of cells used for the formulation of cancer vaccines. It is a method of culturing dendritic cells which are separated from a patient’s own blood, sensitizing antigens expressed by cancer cells, and injecting antigens back into the patient again. Unlike administering antigens only, this method can increase the activity of T-cells by administering after sensitizing APC outside.
D. Liquid Biopsy
For cancer vaccine therapy, cancer antigens must be found through biopsy. If biopsy is difficult, patients may lose an opportunity for treatment. In such cases, cancer antigens can be predicted by detecting tumor DNA in cancer cells circulating in the blood. In addition, after treatment, liquid biopsy can be done through a method for monitoring.